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KCNQ3) Are Responsible for
Dysfunctional Autonomic Control in
Hypertensive Rats
Torill Berg*
Division of Physiology, Department of Molecular Medicine, Institute for Basic Medical Sciences, University of Oslo, Oslo,
Norway
Autonomic dysfunctions play important roles in hypertension, heart failure and
arrhythmia, often with a detrimental and fatal effect. The present study analyzed
if these dysfunctions involved M-channels (members of the Kv7/KNCQ family) in
spontaneously hypertensive rats (SHR). Cardiac output and heart rate (HR) were
recorded by a flow probe on the ascending aorta in anesthetized SHR and
normotensive rats (WKY), and blood pressure (BP) by a femoral artery catheter.
Total peripheral vascular resistance (TPR) was calculated. XE-991 (Kv7.1-7.4-inhibitor)
reduced resting HR in WKY but only after reserpine in SHR. XE-991 increased
TPR and BP baseline in both strains. Retigabine (Kv7.2-7.5-opener) reduced HR,
TPR and BP, also after reserpine. Depolarization induced by 3,4-diaminopyridine
(3,4-DAP), a voltage-sensitive K+ channel (Kv) inhibitor, activated release of both
acetylcholine and norepinephrine, thus activating an initial, cholinergic bradycardia in
SHR, followed by sustained, norepinephrine-dependant tachycardia in both strains.
XE-991 augmented the initial 3,4-DAP-induced bradycardia and eliminated the late
tachycardia in SHR, but not in WKY. The increased bradycardia was eliminated
by hexamethonium and methoctramine (M2muscarinic receptor antagonist) but not
reserpine. Retigabine eliminated the increased bradycardia observed in reserpinized
SHR. XE-991 also increased 3,4-DAP-stimulated catecholamine release, but not after
hexamethonium or reserpine. Conclusions: M-currents hampered parasympathetic
ganglion excitation and, through that, vagal control of HR, in SHR but not WKY. M-
currents also opposed catecholamine release in SHR but not in WKY. M-currents
represented a vasodilatory component in resting TPR-control, with no strain-related
difference detected. Excessive M-currents may represent the underlying cause of
autonomic dysfunctions in hypertension.
Keywords: hypertension, M-channels, parasympathetic ganglia, heart rate, 3, 4-diaminopyridine, Kv7.x,
catecholamines, vascular tension
INTRODUCTION
In hypertension and heart failure, heart rate (HR) is typically controlled by a sympathetic
hyperactivity and parasympathetic hypoactivity (Binkley et al., 1991; Thrasher, 2005), and a high
resting HR is the most reliable predictor of cardiovascular morbidity in man (Palatini, 1999). With
a failing vagal control of HR, sympathetic hyperactivity may lead to hypertensive left ventricular
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hypertrophy (Schlaich et al., 2003), an independent predictor
of morbidity and mortality (Levy et al., 1990). Moreover,
abnormalities in the vagal control of HR may be directly
responsible for a poor outcome in myocardial infarction (Kleiger
et al., 1987), and autonomic dysfunctions also contribute to the
pathology of atrial fibrillation (Park et al., 2012). Dysfunctions in
the balance between parasympathetic and sympathetic control of
HR is therefore detrimental, and may result in a fatal outcome.
In a recent study, hampered vagal control of HR in
spontaneously hypertensive rats (SHR) was located to a reduced
parasympathetic ganglion transmission (Berg, 2015). Evidence
in animal and man indicated that the parasympathetic ganglia
acted as a bottleneck to efferent vagal traffic also in heart
failure (Bibevski and Dunlap, 2011). Neurons are activated
by depolarizing action potentials, which open voltage-sensitive
Ca2+ channels (CaV). The subsequent increase in intracellular
Ca2+ precipitates release of transmitter from vesicles in the
presynaptic nerve terminal. K+ channels have a hyperpolarizing
effect and therefore oppose depolarization and excitation. M-
type, voltage-sensitive K+ channels of the Kv7 family, mainly
Kv7.2-7.3 (KNCQ2-KNCQ3) (Wang et al., 1998), are known to
suppress neuronal excitability and transmitter release throughout
the nervous system (Brown and Passmore, 2009). It was
therefore hypothesized that excessive M-currents hampered
parasympathetic ganglion transmission and in that manner
interfered with vagal control of HR in SHR.
Analysis of the interaction between sympathetic and
parasympathetic control of HR requires both systems to
be activated simultaneously. This is present in conscious
individuals, where Frequency Domain analysis of for instance
respiratory arrhythmia can be used to indicate changes in
parasympathetic activity. However, this arrhythmia depends on
vagal reflexes, and such reflexes are disturbed by the anesthesia
(Berg and Jensen, 2011). However, dual activation of both
parasympathetic and sympathetic autonomic branch can be
achieved in the anesthetized rat by 3,4-diaminopyridine (3,4-
DAP) (Berg, 2015). By blocking presynaptic, voltage-sensitive
K+ channels (Kv) (Vlcková and Stolc, 1990), 3,4-DAP induces
neuronal depolarization, opening of voltage-sensitive Ca2+
channels (CaV) and, thus, transmitter release. 3,4-DAP therefore
mimics the events occurring during nerve stimulation, and may
activate transmitter release in sympathetic and parasympathetic
ganglia, as well as from peripheral autonomic nerves (Figure 1).
An IV injection of 3,4-DAP therefore induced an initial
parasympathetic, atropine-sensitive bradycardia, followed by
a sustained tachycardia elicited by norepinephrine released
from peripheral sympathetic nerve terminals (Berg, 2015). The
parasympathetic component was greater in SHR than in their
normotensive controls (WKY) (Berg, 2015). This difference
was located to the parasympathetic ganglia (Figure 1) (Berg,
2015). If the hyperpolarizing M-channels are closed, neurons are
expected to be more excitable by the depolarization occurring
during an action potential. By studying effects on HR and
catecholamine release, the present study therefore tested if the
role of M-channel in the control of autonomic nerve excitability
in SHR differed from that in WKY (Figure 1), at rest and during
3,4-DAP-induced depolarization.
FIGURE 1 | M-currents are responsible for the vagal dysfunction and
failing autonomic control of HR in SHR. By inhibiting Kv, 3,4-DAP will
induce Ach release primarily from preganglionic parasympathetic neurons and
norepinephrine from sympathetic nerve endings as indicated, and through that
induce bradycardia followed by tachycardia.(Berg, 2015) M-currents
(Kv7.2-7.3) hamper neuron excitability. In the parasympathetic branch, the
M-channels may be located both in the preganglionic and postganglionic
neurons, whereas a postganglionic localization seemed likely in the
sympathetic branch. Drug names indicate site of main action. Arrows and
blunted arrows indicate stimulatory and inhibitory actions, respectively.
Members of the Kv7-family, i.e., Kv7.1, Kv7.4, and Kv7.5
(Mackie et al., 2008), as well as 3,4-DAP-sensitive Kv-channels
(Berg, 2002, 2003), have been detected in rat artery vascular
smooth muscle cells (VSMC), where they oppose depolarization
and the entry of Ca2+ through CaV and in that manner oppose
vasoconstriction. Reduced activation of these currents in VSMC
may therefore contribute to the elevated total peripheral vascular
resistance (TPR) characterizing hypertension. The second goal
of the present experiments was therefore to test if Kv7-currents
influenced TPR and blood pressure (BP) differently in SHR and
WKY.
METHODS
Surgical Procedure
All experiments were approved by The Norwegian Animal
Research Authority (NARA), project license no FOTS2914 and
FOTS8464, and conducted in accordance with the European
Directive 2010/63/EU. Breeding of WKY and SHR, originally
obtained from formally legacyHarlan, now Envigo RMS, Bicester,
Oxfordshire, UK, was done in-house. The rats were kept on a
12/12 h day/night cycle and fed with Teklad Global 18% Protein
Rodent Diet (Teklad Diets, Madison, WI, USA) containing 0.2%
Na+. The SHR (Okamoto, SHR/NHsd strain, n = 88) and
WKY (Wistar Kyoto, n = 36) included in this study, weighed
270 ± 3 g and 267 ± 5 g, respectively, and were 12.2 ± 0.1
and 12.7 ± 0.2 weeks old. The rats were anesthetized with
pentobarbital (65–75mg/kg IP), and the level of anesthesia was
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tested by non-responsiveness to pinching between the toes.When
satisfactory anesthesia was established, it remained throughout
the experimental period without further supply.
After tracheotomy, a heparinized catheter was inserted into
the femoral artery to measure systolic (SBP) and diastolic
(DBP) BP and HR, which at this time was not influenced by
the subsequent, artificial ventilation. The arterial catheter was
connected to a SensoNor 840 transducer (SensoNor, Horten,
Norway). After the starting BP and HR had been recorded,
the rats were connected to a positive-pressure ventilator and
ventilated with air throughout the experiment. The thoracic
cavity was entered through the third intercostal space, and a 2SB
perivascular flow probe, connected to a T206 Ultrasonic Transit-
Time Flowmeter (Transonic Systems Inc., Ithaca, NY, USA),
was placed on the ascending aorta for continuous measurement
of cardiac output (CO, i.e., without cardiac flow) and from
now on also HR. The thoracic cavity was subsequently closed
with a suture. The pressure transducer and flowmeter were
coupled to an amplifier and computer to continuously store and
analyze the data. Mean arterial BP (MBP = SBP-DBP/3+DBP)
and TPR (MBP/CO) were calculated. Body temperature was
maintained at 37–38◦C by external heating, monitored by a
thermo sensor inserted inguinally into the abdominal cavity.
The arterial catheter was subsequently flushed with 0.15ml
buffered saline (PBS; 0.01MNa-phosphate, pH 7.4, 0.14MNaCl)
containing 500 I.U./ml heparin. The animals were injected as
needed with 1–2ml PBS IV to stabilize BP. A period of 10min
was then allowed before the first experimental drug was injected.
Drugs were dissolved in PBS and administered as bolus injections
through a catheter in the femoral vein (0.6–1.3ml/kg), unless
otherwise indicated.
Blood was collected from the arterial catheter at the
end of the 25-min 3,4-DAP-observation-period to determine
the plasma catecholamine concentrations. 3,4-DAP-induced
autonomic activation also stimulates salivary secretion. Whole
saliva was collected with a pipette from the oral cavity
throughout the 3,4-DAP-observation period, and saliva volume
was estimated by weight.
Experimental Protocols
WKY and SHR control rats were pre-treated with an IV sham
injection of vehicle (PBS) and injected 10min later with the
Kv-blocker 3,4-DAP (34.5 µmol/kg, IV), which does not cross
the blood-brain barrier, and which will activate the autonomic
nervous system (Berg, 2015). 3,4-DAP does not interfere with Kv7
(Yeung et al., 2007). In the WKY and SHR experimental groups,
the PBS-sham injection was substituted with either Kv7- blockers,
i.e., XE-991 (Kv7.1-7.4, 2.2 µmol/kg, −10min) (Yeung et al.,
2007) and chromanol 293B (Kv7.1 (Ks), 3µmol/kg,−10 min, not
followed by 3,4-DAP inWKY) (Yang et al., 2004) or Kv7-openers,
i.e., regitabine (Kv7.2-7.5, 4.3 µmol/kg, −30min) (Wickenden
et al., 2000) and ICA-27243 (Kv7.2-7.3, 11.2 µmol/kg, −10min,
tested in SHR only) (Qi et al., 2011).
XE-991 was found to influence the HR-response to 3,4-DAP
in SHR but not in WKY. The ganglion and parasympathetic
and sympathetic involvement in these changes were therefore
further analyzed in SHR only. The nicotinic receptor (nAchR)
involvement was studied by pre-treatment with the ganglion
blocker/nAchR antagonist hexamethonium (37 µmol/kg,
−10min, IV) (Berg, 2005), administered either alone or prior
to XE-991. Influence of norepinephrine release was analyzed
by pre-treatment with reserpine (8.2 µmol/kg, −48 and −24 h,
IP) (Berg, 2002), which depletes sympathetic nerve terminals of
norepinephrine. Postsynaptic muscarinic AchR (mAchR) in the
heart are of the M2-subtype, and are inhibited by the M2mAchR
antagonist methoctramine (Wess et al., 1988). Parasympathetic
involvement was therefore demonstrated by methoctramine
(0.41 µmol/kg,−10min, IV).
The effect of hexamethonium and reserpine alone has been
tested previously inWKY (Berg, 2015) and was not repeated here.
However, only the non-selective mAchR antagonist atropine
has been tested before in WKY, and WKY pre-treated with
methoctramine were therefore included in the present protocol.
Measurement of Plasma Catecholamines
1.5 ml blood was collected from the femoral artery into tubes
containing 45 µl 0.2 M glutathione and 0.2 M ethylene glycol-
bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA)
(4◦C). Plasma was stored at −80◦C until catecholamine
concentrations were determined using 400 µl plasma and the
5000 Reagent kit for HPLC analysis of Catecholamines in plasma
from Chromsystems GmbH, Munich, Germany, as described
by the manufacturer. The samples were run on a Shimadzu
monoamines analyzer system, using an isocratic flow rate of
0.8ml/min, and an electrochemical detector (Decade II) and a
SenCell electrochemical flow cell (Antec Leyden, Zoeterwoude,
The Netherlands).
Drugs
Pentobarbital was obtained from The Norwegian National
Hospital, Oslo, Norway; retigabine (ethyl-(2-amino-4-(4-
fluorobenzylamino)-phenyl)carbamate dihydrochloride)
and XE-991 dihydrochloride (10,10-bis(4-pyridinylmethyl)-
9(10H)-anthracenone) from MedChem Express, Princeton,
NJ, USA; chromanol 293B (trans-N-[6-Cyano-3,4-dihydro-
3-hydroxy- -2,2-dimethyl-2H-1-benzopyran-4-yl]-N-methyl-
ethanesulfonamide) from Tocris Bioscience, Bristol, UK;
ICA-27243 (N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide)
from Alomone Labs, Jerusalem, Israel; and methoctramine
hydrate (N,N’-bis[6-[(2-methoxybenzyl)amino]hexyl]-1, 8-
octanediamine tetrahydrochloride) from Sigma Chemical Co.,
St. Louis, MO, USA.
Statistical Analyses
Each group comprised 6-9 rats. All results are presented as mean
values± s.e.mean. The cardiovascular data recorded throughout
the experiments were averaged every minute, except during
the initial response to PBS, XE-991, chromanol, retigabine,
ICA-27243 or 3,4-DAP, where data were averaged every 7th
heart-beat. The latter HR-response was recorded at the same
time as the highest/lowest TPR-response was detected, even
if a different HR was seen before that. The cardiovascular
response to pre-treatment, baselines prior to 3,4-DAP, saliva
volume and the plasma catecholamine concentrations were
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evaluated over-all by one-way ANOVA, including all groups
within each strain. When the presence of group differences
was indicated, these were located by two-tailed, two-sample
Student’s t-tests for parametric data, and by Kruskal-Wallis
tests for non-parametric data. The 3,4-DAP-response curves
included values recorded at the initial TPR peak-response, i.e.,
at about 1–1.5min, and during the late response, i.e., at 10,
15, 20, and 25min. Since TPR is determined by the vessel
radius in the fourth power, changes in TPR were expressed in
percent of before values. The 3,4-DAP-response curves were
analyzed using Repeated Measures Analyses of Variance and
Covariance, first as over-all tests including all groups within
each strain, and subsequently between groups or for each group
separately. Group differences (two-tailed, two-sample Student’s
t-tests or Kruskall-Wallis tests) were subsequently located at
specific times, i.e., during the initial response and at the end
of the experiment. Testing proceeded only when the presence
of significant responses, differences and/or interactions was
indicated. The P-value was for all tests and each step adjusted
according to Bonferroni, except for saliva volume and the plasma
catecholamine concentrations, where P ≤ 0.05 was considered
significant.
RESULTS
The Cardiovascular Response to
Kv7-Inhibitors/Openers at Rest
At the beginning of surgery, i.e., before the rats were connected
to the ventilator, MBP was 79 ± 3 and 133 ± 6 mmHg in
WKY and SHR, respectively (P < 0.001, pooled data for all non-
reserpinized rats). HR at this time was 306 ± 7 and 389 ± 5
bpm, respectively (P < 0.001). Prior administration of reserpine
in SHR (not tested in WKY) lowered these parameters to 95 ±
3 mmHg and 311 ± 5 bpm (P < 0.001). After being connected
to the positive-pressure ventilator and thoracotomized, MBP
was reduced (P < 0.001) to 61 ± 2 mmHg in WKY and to
79 ± 3 mmHg in SHR, since SHR were more sensitive than
WKY to the reduced venous return to the right heart due to
the ventilator-dependent intrathoracic pressure. HR at this time
was 339 ± 8 bpm in WKY (P = 0.003 compared to before)
and 398 ± 5 bpm in SHR (P = NS). The PBS-sham-injection
had little effect on the cardiovascular baselines, and MBP, HR,
and TPR prior to 3,4-DAP were higher in SHR than in WKY
(Table 1).
Effect of pre-treatment and the cardiovascular baselines after
pre-treatment are shown in Table 1. In short, the ganglion
blocker hexamethonium reduced MBP, HR and TPR, and MBP
remained low after reserpine (tested in SHR only). However, the
M2mAchR antagonist methoctramine increased baseline HR and
TPR in SHR and HR in WKY (P ≤ 0.008).
The Kv7.1-7.4-inhibitor XE-991 induced an acute (Figure 2)
but transient reduction in baseline HR in WKY (P = 0.005).
In SHR, XE-991 induced bradycardia only after reserpine (P
< 0.001). The Kv7.1-inhibitor chromanol had no effect on
resting HR in either strain (P = NS) (Figure 2). The Kv7.2-
7.5-opener retigabine induced a transient bradycardia in both
strains (P < 0.001), and also in reserpinized SHR (Figure 2).
The Kv7.2-7.3-opener ICA-27243, alone or after reserpine, had
no significant effect on baseline HR.
XE-991 induced an immediate, but transient rise in TPR (P ≤
0.002) of equal magnitude in the two strains (Figure 2). The TPR-
response was not different after reserpine or methoctramine but
was eliminated by hexamethonium (tested in SHR). Chromanol
had no significant effect on baseline TPR in either strain.
The Kv7-opener retigabine precipitated a transient reduction in
baseline TPR (P < 0.001, P = NS for a strain-related difference).
This reduction was not influenced by reserpine (tested in SHR).
The TPR-response to ICA-27243 was not statistically significant
(tested in SHR). These changes in TPR were paralleled by similar
changes in MBP (Figure 2). Significant changes in CO were not
observed (not shown).
XE-991 induced myokymia in all rats, starting within
the first minute, first as a shivering in the facial muscles,
later extending into the thorax and abdomen. XE-991-
induced myokymia was observed also after hexamethonium,
reserpine or methoctramine. XE-991 did not evoke
salivation.
Effect of Kv7-Inhibitors/Openers On
3,4-Dap-Induced Changes in the Plasma
Catecholamine Concentrations (Table 2)
The concentration of norepinephrine in plasma collected at the
end of the 3.4-DAP-observation-period was greater than that
previously observed in time controls given PBS instead of 3,4-
DAP in SHR (P ≤ 0.004) but not in WKY. The secretion
of epinephrine was stimulated by the experiment itself (Berg
et al., 2012), and the concentration of epinephrine in the 3,4-
DAP controls did not differ from that previously observed
in time-controls. The norepinephrine but not epinephrine
concentration was higher in SHR than in WKY (P ≤
0.003).
Hexamethonium and reserpine alone reduced the 3,4-
DAP-induced norepinephrine overflow in SHR (P = 0.046),
and hexamethonium, but not reserpine, lowered also the
concentration of epinephrine (P = 0.01). Methoctramine alone
increased norepinephrine overflow (P = 0.047 compared to the
controls) but not epinephrine in SHR, and had no effect in
WKY. XE-991 caused a minor increase in the concentration of
norepinephrine (P = 0.01) but not epinephrine in WKY, but
greatly increased the concentration of both catecholamines in
SHR (P ≤ 0.005). Hexamethonium and reserpine eliminated
the XE-991-dependant, increased norepinephrine overflow in
SHR (P ≤ 0.015 compared to XE-991 alone, P = NS
compared to the controls), but the concentration remained
slightly higher than that after hexamethonium or reserpine alone
(P ≤ 0.025). Hexamethonium and reserpine also eliminated
the XE-991-induced, increased secretion of epinephrine in
SHR (P = 0.002 compared to XE-991 alone, P = NS
compared to the controls). Methoctramine did not alter
the augmenting effect of XE-991 on catecholamine release.
Chromanol, retigabine and ICA-47242 did not influence
the 3,4-DAP-induced changes in the plasma catecholamine
concentrations.
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TABLE 1 | Cardiovascular baselines after pre-treatment, and the response to pre-treatment below in parenthesis.
Pre-treatment WKY SHR
MBP mmHg HR bpm CO ml/min TPR mmHg/ml/min MBP mmHg HR bpm CO ml/min TPR mmHg/ml/min
PBS 61± 4 339± 12 28±1 2.2± 0.1 89± 10* 388±12** 31± 3 2.9± 0.2**
(−3± 2) (−16± 3) (0±1) (−0.2± 0.0) (−4± 4) (−11±8) (2± 1) (−0.3± 0.1)
PBS after reserpinea 64± 4† 361±12 27± 2 2.4± 0.1
(−4± 2) (−16±5) (−1± 0) (−0.1± 0.0)
Methoctramine+PBS 60± 2 366± 7 31±2 2.0± 0.1 83± 6 458±11††† 21± 2† 4.0± 0.3††
(−1± 2) (32± 12)†† (3±1) (−0.3± 0.1) (12± 7) (50±17)†† (−1± 1) (0.6± 0.2)††
Hexamethonium 53± 2†† 345±19† 25± 1 2.9± 0.2
(−33± 7)†† (−67±8)††† (−1± 1) (−1.4± 0.2)††
XE-991 48± 3† 290± 22 32±6 1.8± 0.3 65± 3† 384±13 24± 1 2.8± 0.2
(−7± 5) (−43± 24) (5±3) (−0.4± 0.2) (−14± 5) (−21±15) (2± 1) (−0.8± 0.2)
XE-991 after reserpinea 61± 4† 340±10† 31± 1 2.0± 0.1††
(−12± 3) (−41±12) (4± 1) (−0.7± 0.1)
Methoctramine+XE-991 66± 8 442±8†† 21± 2† 3.2± 0.2
(−16± 7) (50±6)††† (0± 1) (−0.8± 0.5)
Hexamethonium+XE-991 49± 3†† 334±10†† 16± 2†† 3.2± 0.2
(−43± 5)††† (−71±13)†† (−2± 1)† (0.4± 2.5)
Chromanol 293B 68± 4 340± 14 30±2 2.4± 0.2 65± 9 369±11 17± 2†† 3.8± 0.3†
(−4± 1) (−2± 5)† (2±1) (−0.3± 0.1) (−14± 5) (−21±7) (−2± 0)† (−0.4± 0.2)
Retigabine 53± 3 310± 17 36±2†† 1.5± 0.1††† 64± 6 363±10 22± 1† 3.2± 0.3
(−2± 3) (−5± 4)† (4±1)† (−0.2± 0.1) (−8± 2) (−23±10)† (2± 0) (−0.3± 0.3)
Retigabine after reserpinea 63± 4† 354±6† 28± 2 2.3± 0.2†
(−9± 1) (−23±4) (1± 1) (−0.4± 0.1)
ICA-27243 61± 5† 377±5 19± 1††† 3.3± 0.2
(−3± 5) (−31±8) (0± 0) (−0.1± 0.2)
ICA-27243 after reserpinea 75± 5 349±8† 26± 2 2.9± 0.2
(−1± 3) (−25±6) (0± 1) (−0.1± 0.1)
aReserpine was administered prior to the experiment, and the effect of reserpine combined with PBS, XE-991, retigabine or IC-27243 are therefore indicated by the differences in
baselines prior to 3,4-DAP, whereas the response to PBS, XE-991 or retigabine in reserpinized SHR are shown in parenthesis below. Significant differences between the WKY and SHR
control groups (*), between corresponding control and experimental groups (
†
) were detected as indicated. *,
†
P ≤ 0.05, **,
††
P ≤ 0.01, and
†††
P ≤ 0.001.
Effect of Kv7-Inhibitors/Openers On the
HR-Response to 3,4-DAP
As previously described (Berg, 2015), the Kv-blocker 3,4-
DAP induced depolarization and in that manner activated the
autonomic nervous system. 3,4-DAP therefore induced an initial
bradycardia, but in SHR only (P < 0.001) (Figure 3). Thereafter,
HR increased, and a sustained tachycardia was observed in both
strains (P < 0.0001). 1HR after 25 min was higher in SHR
than in WKY (P = 0.008). Hexamethonium and methoctramine
abolished the initial 3,4-DAP-induced bradycardia in SHR
(Figures 3B,D), whereas reserpine eliminated the subsequent
tachycardia (Figure 3C). In agreement with previous conclusions
(Berg, 2015), these results demonstrated that the 3,4-DAP-
induced bradycardia in SHR involved activation of cardiac,
parasympathetic ganglia, whereas the tachycardia involved
sympathetic nerve norepinephrine release. Methoctramine had
no significant effect on the HR-response to 3,4-DAP in WKY
(Figure 3A).
The M-current blocker XE-991 had no effect on the HR-
response to 3,4-DAP in WKY (Figure 3A). In SHR, XE-991
enhanced the initial bradycardia and eliminated the subsequent
tachycardia (P ≤ 0.025). The changes induced by XE-991 in
SHR were further analyzed to identify possible ganglionic,
parasympathetic and sympathetic involvement. The ganglion
blocker hexamethonium abolished the initial bradycardia in the
XE-991-treated SHR (P ≤ 0.003 compared to controls or XE-
991 alone, Figure 3B). Hexamethonium also restored the failing
tachycardia in the XE-991-treated SHR (P = 0.001). There was
no difference between SHR groups pre-treated with XE-991 and
reserpine+XE-991 (Figure 3C). Methoctramine abolished the
initial 3,4-DAP-activated bradycardia in the XE-991-treated SHR
(P = 0.008 compared to the XE-991-only group, Figure 3D),
but a late tachycardia was not observed in these rats (P = 0.005
compared to SHR controls). Chromanol had no effect on the
HR-response to 3,4-DAP in SHR (Figure 3D).
The Kv7.2-7.5-opener retigabine had no significant effect on
the HR-response to 3,4-DAP in WKY (Figure 4). The initial
3,4-DAP-induced bradycardia was no longer significant in SHR
after retigabine, and both retigabine and the Kv7.2-7.3-preferring
ICA-27243 eliminated the enhanced bradycardia in reserpinized
SHR (P ≤ 0.006). Both drugs also slightly enhanced the late
3,4-DAP-induced tachycardia in SHR (P = 0.02), but did not
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FIGURE 2 | The acute HR-, TPR-, and MBP-response to KV7-inhibitors and -openers. Preferred drug selectivity is indicated by symbol legends. The drugs
were given alone or, in SHR, in combination as indicated. The immediate HR- and MBP-response was recorded at the initial TPR-peak/nadir-response. Significant
changes in response to channel inhibitors/openers compared to that following the sham-injection of PBS in the control groups were detected as indicated (asterix
below/above columns). Involvement of ganglion transmission, sympathetic nerve norepinephrine release and M2AchR activity in the response to Kv-drug was further
analyzed in SHR by prior administration of hexamethonium, reserpine or methoctramine, respectively (* in bar). * above columns—P ≤ 0.0167 in WKY and 0.0056 in
SHR. * in brackets—P ≤ 0.0167 for XE-991 (none detected) and 0.025 for retigabine.
TABLE 2 | The concentration of catecholamines in plasma after 3,4-DAP.
Groups WKY SHR
Norepinephrine (nM) Epinehrine (nM) Norepinephrine (nM) Epinephrine (nM)
Time controls (PBS+PBS)a 0.5± 0.0 7.9±1.6 1.2±0.2† 10.8± 2.7
PBS+3,4-DAP 1.1± 0.2 8.5±1.4 5.5±0.6* 18.5± 5.2
Hexamethonium+3,4-DAPb 2.5±0.3† 3.4± 1.0†
Reserpine+PBS+3,4-DAP 1.1±0.6† 11.1± 2.6
Methoctramine+PBS+3,4-DAP 1.1± 0.1 7.7±3.2 13.1±2.8† 26.9± 11.8
XE-991+3,4-DAP 3.3± 0.7† 11.6±4.2 35.6±9.1† 125.5± 27.4†
Hexamethonium+XE-991+3,4-DAP 11.5±3.6‡⊢ 35.9± 12.6‡⊢
Reserpine+XE-991+3,4-DAP 4.4±0.9‡⊢ 17.2± 4.0‡
Methoctramine+XE-991+3,4-DAP 35.7±7.3†⊢ 88.1± 28.7†
Chromanol+3,4-DAP 6.8±2.1 35.0± 23.5
Retigabine+3,4-DAP 0.8± 0.2 3.9±1.4 4.7±0.5 12.3± 2.2
Reserpine+retigabine+3,4-DAP 1.0±0.3†‡ 9.7± 2.1‡
ICA-27243+3,4-DAP 6.5±2.3 18.5± 11.5
Reserpine+ICA-27243+3,4-DAP 1.4±1.0† 5.8± 2.0
Arterial blood was collected at the end of the experiment. Significant differences between the WKY and SHR 3,4-DAP controls (*), between the 3,4-DAP-control and experimental
groups within each strain (
†
), and in SHR between corresponding groups pre-treated with channel drug and reserpine/ hexamethonium/methoctramine+channel drug (
‡
), and between
corresponding groups pre-treated reserpine/hexamethonium/methoctramine and reserpine/ hexamethonium/methoctramine+channel drug (⊢ ) were detected as indicated.
a most rats in this groups was from Berg and Jensen (2011).
b from Berg (2015). *,
†
,
‡
, ⊢ P < 0.05.
interfere with the reserpine-dependant inhibition on the late
tachycardia.
Effect of Kv7-Inhibitors/Openers On the
TPR-Response to 3,4-DAP
3,4-DAP also induced an immediate rise in TPR (P < 0.0001),
which did not differ in the two strains (P = NS) (Figure 5).
TPR returned quickly to baseline in WKY, but remained elevated
in SHR (P = 0.017) and was higher than that observed
in WKY (P = 0.007). Reserpine had no significant effect
on the immediate TPR-peak-response in SHR but eliminated
the elevated, late TPR-response to 3,4-DAP (P = 0.015,
Figure 5C).
XE-991 reduced the TPR-peak-response to 3,4-DAP in WKY
(P = 0.015, Figure 5A) but had no significant effect in SHR
(Figure 5B). XE-991 did not alter the late TPR-response to 3,4-
DAP in either strain (Figures 5A,B). Kv7 inhibitor/openers had
otherwise no effect on the TPR-response to 3,4-DAP, and did
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FIGURE 3 | The HR-response to 3,4-DAP after pre-treatment with the KV7.1-7.4-inhibitor XE-991 in WKY (A) and SHR (B–D), pre-treated as indicated by
symbol legends. Significant responses (* within symbol) and group differences (* in brackets) at about 1 (recorded at the TPR-peak-response) and at 25 min were
located as indicated. Comparisons were made between corresponding control and experimental groups, and between the SHR groups pre-treated with
hexamethonium/reserpine/methoctramine alone and hexamethonium/reserpine/methoctramine+XE-991. *P < 0.025 after curve analyses.
FIGURE 4 | The HR-response to 3,4-DAP after pre-treatment with
Kv7-openers. Retigabine (KV7.2-7.5) and ICA-27243 (KV7.2-7.3) were
administered alone or after reserpine, as indicated by symbol legends.
Significant responses (* within symbol) and group differences (* in brackets) at
about 1 (recorded at the TPR-peak-response) and at 25 min were located as
indicated. Comparisons were made between corresponding control and
experimental groups, and between groups pre-treated with
retigabine/ICA-27243 alone and reserpine+retigabine/ICA-27243. *P < 0.025
after curve analyses.
not interfere with the inhibitory effect of reserpine in SHR
(Figures 5C,D). However, reserpine+XE-991 clearly reduced the
TPR-response throughout the 3,4-DAP-observation-period in
SHR (Figure 5C) The changes in MBP largely followed these
changes in TPR (not shown).
Effect of Kv7-Inhibitors/Openers on
3,4-DAP-Induced Salivation (Table 3)
3,4-DAP activated secretion of saliva with a greater effect
in WKY than in SHR (P ≤ 0.045). Salivation in SHR was
reduced by 81 and 74% after reserpine and hexamethonium,
respectively (P ≤ 0.014). Methoctramine enhanced the 3,4-DAP-
induced salivation in WKY (P = 0.017), but had no effect
in SHR. XE-991 and chromanol had no significant effect on
saliva volume. The channel opener retigabine reduced the 3,4-
DAP-induced salivation in WKY (P = 0.009). Retigabine and
ICA-27243 had no significant effect in SHR. XE-991, retigabine
and ICA-27243 did not interfere with the lowering effect of
reserpine, but XE-991 eliminated the reduction induced by
hexamethonium (tested in SHR only). Salivation in SHR pre-
treated with methoctramine+XE-991 was not different from that
in the controls or after methoctramine alone.
DISCUSSION
The main result in the present study was that inhibition of
hyperpolarizing M-channels, most likely Kv7.2-7.3, enhanced
parasympathetic ganglion transmission and vagal control of
HR in SHR, and also increased sympathetic nerve and adrenal
catecholamine release in this strain, but had little effect in WKY.
Vascular M-channels, i.e., Kv7.4 and possibly also 7.5, had a
vasodilatory effect on resting TPR in both strains.
Role of M-Currents in Catecholamine
Release
In unstimulated rats, the plasma norepinephrine concentrations
are low due to re-uptake through the norepinephrine re-
uptake transporter, and differences in release are difficult
to demonstrate (Berg et al., 2012; Berg and Jensen, 2013).
Autonomic nerve transmitter release was therefore stimulated
by depolarization, induced by inhibition of presynaptic Kv
by 3,4-DAP. 3,4-DAP itself does not inhibit IM (Goh et al.,
1989). Previous analyses showed that 3,4-DAP stimulated
release primarily in the parasympathetic ganglia and in
sympathetic nerve terminals (Berg, 2015; Figure 1). Inhibition
of the stabilizing M-channels with XE-991, but not chromanol,
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FIGURE 5 | The TPR-response to 3,4-DAP in WKY (A) and SHR (B–D) after pre-treatment with Kv7-opener or -inhibitor, alone or combined with hexamethonium,
reserpine or methoctramine, as indicated by symbol legends. Significant responses (* within symbol) and group differences (* in brackets) at about 1 (at the
TPR-peak-response) and at 25min were located as indicated. Comparisons were made between corresponding control and experimental groups, and between
groups pre-treated with corresponding channel opener/inhibitor alone and hexamethonium/reserpine/methoctramine+channel opener/inhibitor. *P < 0.025 after
curve analyses.
TABLE 3 | Effect of KV7-inhibitors/openers on 3,4-DAP-induced salivation.
Groups Saliva volume (µl)
WKY SHR
PBS+3,4-DAP (control) 394± 96 131±52*
Hexamethonium+3,4-DAP 34±2†
Reserpine+PBS+3,4-DAP 25±11†
Methoctramine+PBS+3,4-DAP 737± 70† 124±25
XE-991+3,4-DAP 319± 118 72±27
Hexamethonium+XE-991+3,4-DAP 177±67
Reserpine+XE-991+3,4-DAP 49±22†
Methoctramine+XE-991+3,4-DAP 176±51
Chromanol+3,4-DAP 114±12
Retigabine+3,4-DAP 115± 34† 71±50
Reserpine+retigabine+3,4-DAP 14±13†
ICA-27243+3,4-DAP 72±21
Reserpine+ICA-27243+3,4-DAP 31±9†
Salivation does not occur in anesthetized rats, unless stimulated, as here by the
3,4-DAP-induced activation of the autonomic nervous system. Significant differences
between the WKY and SHR control groups (*), between corresponding control
and experimental groups (
†
) and between corresponding groups pre-treated with
XE-991/retigabine/ICA-27243 alone and reserpine/hexamethonium/methoctramine+XE-
991/retigabine/ICA-27243 (none detected) were detected as indicated. *,
†
P < 0.05.
induced a large increase in norepinephrine overflow to plasma
and epinephrine secretion in SHR, but had little effect in
WKY. M-currents, most likely Kv7.2-7.3, therefore strongly
opposed the release of both norepinephrine and epinephrine
in SHR, but not in WKY. As expected, the XE-991-dependant
stimulation of norepinephrine release was eliminated by
reserpine. Unexpectedly, reserpine also abolished the increased
secretion of epinephrine, possibly indicating that sympathetic
nerves or the high level of circulating norepinephrine stimulated
the secretion of epinephrine. However, it could not be excluded
that this effect of reserpine involved a central action. Also
hexamethonium eliminated the XE-991-dependant increased
catecholamine secretion. The effect on epinephrine secretion
was explained by inhibition of the adrenal, postsynaptic
nAchR, a prime activator of adrenal epinephrine secretion.
This conclusion was confirmed by that hexamethonium also
alone reduced the secretion of epinephrine. The effect of
hexamethonium on the increased norepinephrine overflow
after XE-991+3,4-DAP as well as after 3,4-DAP alone, may
result from inhibition of presynaptic nAchR, which facilitate
the release of norepinephrine (Haass and Kübler, 1997). This
observation suggested that IM depended on Ach, which may
be released from the preganglionic neuron or from adjacent
parasympathetic nerve fibers (Figure 1). The two-fold increase
in the plasma norepinephrine but not epinephrine concentration
in SHR pre-treated with methoctramine alone was compatible
with inhibition of presynaptic M2mAchR, known to inhibit
norepinephrine release from sympathetic nerves (Jumblatt
and Hackmiller, 1994). A similar effect was not observed
in WKY. Presynaptic M2mAchR evidently did not influence
sympathetic nerve M-currents since methoctramine did not
hamper the increased catecholamine concentrations in XE-991-
treated SHR.
Role of M-Currents in Resting HR-Control
Since hyperpolarizing M-currents oppose nerve excitability,
the fall in resting HR in response to the KV7.1-7.4-preferring
inhibitor XE-991 (Yeung et al., 2007) in WKY was likely
to reflect an increased parasympathetic activity, rather than
a decrease in the sympathetic control of HR. A role of
cardiac KV7.1 (KS), which contributes to repolarization
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in the heart, was excluded, since chromanol did not
influence resting HR. It was therefore concluded that
members of the Kv7-family, most likely KV7.2-7.3, were
open in WKY and sustained resting HR by inhibiting vagal
transmission.
XE-991 destabilized also sympathetic nerves, and an XE-
991-induced, parasympathetic bradycardia was detected in SHR
only after the sympathetic nerve terminals were depleted of
norepinephrine by reserpine. Thus, the stimulating effect of
XE-991 on resting, parasympathetic HR-control was hampered
in SHR by the simultaneous increase in sympathetic nerve
activity. This conclusion was supported by that XE-991 increased
3,4-DAP-induced catecholamine release predominantly in
SHR, as discussed above. This IM-dependant autonomic
imbalance in SHR may explain the high resting HR in this
strain.
The Kv7-opener retigabine (KV7.2-7.5) reduced resting HR
equally in the two strains, compatible with a reduced neuronal
and/or adrenal catecholamine release. However, retigabine
induced bradycardia also in reserpinized SHR, which may
be due to that adrenergic HR-control after reserpine relied
on epinephrine. However, retigabine may stimulate GABA
synthesis and GABA-activated Cl− channels (Kapetanovic et al.,
1995; Rundfeldt and Netzer, 2000), which may in the central
nervous system influence resting HR. The latter explanation
was supported by the fact that ICA-27243 (KV7.2-7.3-preferring)
failed to lower resting HR in SHR.
Role of M-Currents in HR-Control in the
Stimulated Heart
M-channels are likely to be more open during nerve
depolarization. Through changes in HR, 3,4-DAP-induced
neuronal depolarization offered the opportunity to study the role
of M-channels in not only sympathetic but also parasympathetic
excitation. XE-991 enhanced the immediate 3,4-DAP-induced
bradycardia. This effect was eliminated by methoctramine,
indicating activation of parasympathetic, postsynaptic mAchR
(Figure 1), which are of the M2-sutype in the heart (Wess et al.,
1988) Furthermore, reserpine, by eliminating the counter-acting
effect of norepinephrine release, enhanced the 3,4-DAP-induced
bradycardia, but did not alter the effect of XE-991 on the
immediate HR-response to 3,4-DAP. Also hexamethonium
abolished the increased bradycardia in XE-991-treated SHR.
These observations located the stimulating effect of XE-991 to
the parasympathetic ganglia. It was therefore concluded that
M-currents hampered vagal control of HR in SHR, apparently by
hampering parasympathetic ganglion transmission. XE-991 had
no effect on the HR-response to 3,4-DAP inWKY, indicating that
M-currents did not hamper vagal function in normotensive rats.
An inhibitory effect of IM on parasympathetic signaling,
was further supported by the absence of an immediate,
3,4-DAP-induced bradycardia in SHR pre-treated with the
Kv7-opener retigabine, and, even more, by that retigabine
and ICA-27243 eliminated the enhanced bradycardia in
reserpinized SHR. The latter result excluded that the role
of M-currents in the initial 3,4-DAP-induced bradycardia
involved reductions in sympathetic activity. In agreement
with a reduced parasympathetic activation in the presence of
M-channel openers, both Kv-openers also enhanced the late
3,4-DAP-induced tachycardia in SHR. Like XE-991, the effect
of retigabine on the HR-response to 3,4-DAP in WKY was not
statistically significant, compatible with a role of M-currents in
parasympathetic and sympathetic nerve excitability in SHR only.
Methoctramine and XE-991, separately or combined, also
eliminated the late 3,4-DAP-induced tachycardia in SHR, in
spite of high levels of circulating catecholamines in SHR given
XE-91. The reasons underlying these observations were not
clear, and similar effects were not observed after methoctramine
or XE-991 in WKY. However, the inhibitory effect of XE-991
may be due to a dominating effect of the XE-991-induced
parasympathetic activation. This conclusion was supported by
that the tachycardia was restored by hexamethonium, which
through ganglion blockade will eliminate the XE-991-activated
parasympathetic excitation.
Neuronal M-currents are primarily mediated through
KV7.2-7.3 (Wang et al., 1998), compatible with the present
Kv7-inhibitor profiles, although the presents results did not
exclude a role of Kv7.4. Neuronal M-channels are clustered in
the axonal initial segment and in the nodes of Ranvier (Pan
et al., 2006; Figure 1). However, M-channels have also been
detected in the preganglionic vagal nerve fibers together with
the 4-aminopyridine-sensitive Kv1.1 (Glasscock et al., 2012).
The inhibitory effect of the nAChR antagonist hexamethonium
on the XE-991-stimulated parasympathetic bradycardia may
be interpreted in support of both a preganglionic and a
postganglionic M-channel localization in the parasympathetic
branch (Figure 1). However, although hexamethonium
blocked the effect of XE-991 on norepinephrine release, it
did not prevent the late, 3,4-DAP-induced, norepinephrine-
dependant tachycardia in SHR. The M-channels may therefore
possibly have a postganglionic localization in the sympathetic
branch.
Role of M-Currents in TPR-Control
Vasodilatory KV7.1, 7.4, and 7.5 have been demonstrated in
rat arterial VSMC (Mackie et al., 2008), although an additional
presence in the endothelium could not be excluded. XE-
991 increased, and retigabine reduced resting TPR, whereas
the Kv7.1- and 7.2-7.3-preferring drugs chromanol and ICA-
27243 had no effect. These responses were not different in
reserpinized SHR. It was therefore concluded that M-channels,
most likely KV7.4 and possibly also 7.5, controlled VSMC
tension, independent of norepinephrine release. No strain-
related difference was detected. This result differed from that
previously observed in in vitro studies, where Kv7.4-mediated
arterial vasodilatation was found to be reduced in SHR (Jepps
et al., 2011; Chadha et al., 2012). The vasoconstrictory TPR-
response to XE-991 was also not influenced by M2AchR
antagonist, indicating that the VSMC M-currents were not
activated by M2AchR. Methoctramine itself increased resting
TPR in SHR, possibly due to increased norepinephrine release,
compatible with that observed after 3,4-DAP-stimulation, as
discussed above. Increased norepinephrine release may also
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explain why methoctramine increased resting HR in both
strains, but this increase may also be explained by inhibition of
postsynaptic M2mAchR, which mediate vagal function in the
heart. The XE-991-induced vasoconstriction observed in SHR
was totally eliminated by hexamethonium. This observation may
suggest an inhibitory effect of nAchR on M-currents in VSMC,
in accordance with the transient rise in TPR following injection
of nicotine (Berg, 2015). However, other mechanisms may be
involved.
The injection of 3,4-DAP precipitated an immediate rise in
TPR in both strains. This was likely to primarily result from
inhibition of 3,4-DAP-sensitive Kv in the VSMC (Berg, 2002,
2003). The TPR-response was transient in WKY, but sustained
in SHR, and the late vasoconstriction in SHR depended on
the 3,4-DAP-induced release of norepinephrine since it was
eliminated by reserpine. The Kv7-inhibitors/openers had no
clear, decipherable effect on the TPR-response to 3,4-DAP,
possibly because IM were likely to influence VSMC contractility
through the same mechanisms as 3,4-DAP, i.e., altering the
VSMC membrane potential by altering K+ conductance,
thus influencing CaV and the entry of Ca2+. 3,4-DAP was
therefore not suitable for studying the impact of M-currents on
norepinephrine-stimulated vasoconstriction.
Role of M-Currents in 3,4-DAP-Induced
Salivation
The 3,4-DAP-induced salivary flow apparently depended on
parasympathetic activation since it was almost totally abolished
by atropine (Berg, 2015) but not inhibited by methoctramine,
in accordance with that parasympathetic salivation is mediated
primarily by M3, but also by M1 and M4 mAchR (Bymaster
et al., 2003). However, salivation was also reduced by reserpine
in SHR and by the β-adrenoceptor blocker nadolol in both
strains (Berg, 2015), indicating dependence of sympathetic
nerve activation. 3,4-DAP-induced saliva also contained a
high concentration of kallikrein in SHR, the secretion of
which depends on α-adrenoceptor activation (Berg, 2015). The
reduced salivation observed after hexamethonium, may therefore
also be explained by inhibition of presynaptic nAchR, which
facilitate release of norepinephrine (Haass and Kübler, 1997).
The augmenting effect of methoctramine on 3,4-DAP-induced
salivation in WKY was likely to result from inhibition of
presynaptic M2mAchR, which inhibit norepinephrine release
from sympathetic nerves (Jumblatt and Hackmiller, 1994). The
3,4-DAP-induced salivation therefore appeared to depend on
sympathetic nerve activation, modulated by presynaptic nAchR
or mAchR, activated by the 3,4-DAP-induced release of Ach.
In spite of the XE-991-induced increased catecholamine release,
only retigabine reduced salivation and in WKY only, explained
by reduced neuronal excitability.
Myokymia
XE-991 activated myokymia in both strains, fully compatible
with the antiepileptic effect of retigabine by opening KV7.2-7.3
(Wickenden et al., 2000). The impact of IM on autonomic control
in SHR revealed by the present experiments, may indicate a need
for analyses of possible beneficial or unwanted side-effects of IM-
openers as antiepileptic therapy in cardiovascular risk patients. It
may also be considered if sudden death in epilepsy may involve
Kv7-dependant cardiac autonomic dysfunctions.
CONCLUSIONS
The present study showed for the first time that M-channels
stabilized parasympathetic nerves and inhibited vagal control
of HR in SHR but not WKY. M-channels also opposed
release of norepinephrine and epinephrine, and, when inhibited,
massive catecholamine release was observed in response to nerve
stimulation, but only in SHR. The up-regulation of the stabilizing
M-currents in SHR may be a primary defect causing sympathetic
tone to rise, but may also be a compensation for an up-regulated
central sympathetic output. The M-channel-dependent changes
observed in SHR are likely to play an important role in the
dysfunctional autonomic control of HR in hypertension and
possibly also in heart failure, myocardial infarction and atrial
fibrillation. In addition, M-channels were demonstrated to play
a clear role in down-regulating VSMC resting tension and TPR,
but with no strain-related difference detected. The M-channels
controlling neuronal excitation were likely to be Kv7.2-7.3,
whereas Kv7.4, possibly also Kv7.5, regulated vascular tension.
Thus, channel-specific drugs may allow selective manipulation
of neuronal and vascular M-currents, and may have a future as
antihypertensive or antiarrhythmic therapeutics.
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